apoaequorin

recombinant calcium binding protein; component of aequorin

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Body Weight (Weight, Body) 07/01/2013 - "For this study, Sprague-Dawley (Hsd:SD) rats (10/sex/group) were administered via oral gavage 0 (control), 92.6, 462.9, and 926.0mg/kg body weight (bw)/day of Apoaequorin preparation, for 90 days. " 07/01/2013 - "There were no clinical or ophthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology or histopathological changes attributable to administration of Apoaequorin. "
2.	Shock 05/07/2004 - "Cosuppression of NtTPC1s in apoaequorin-expressing BY-2 cells resulted in inhibition of rise in cytosolic free Ca(2+) concentration ([Ca(2+)](cyt)) in response to sucrose and a fungal elicitor cryptogein, while it did not affect hypoosmotic shock-induced [Ca(2+)](cyt) increase. "
3.	Ischemia 11/01/2020 - "Our laboratory has previously shown that the calcium-binding protein apoaequorin (AQ) is neuroprotective during oxygen-glucose deprivation, a model of in vitro ischemia characterized by calcium-induced excitotoxicity. "